PTC pulls file for Duchenne therapy on FDA feedback
PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy treatment Translarna.
Newsletters and Deep Dive digital magazine
PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy treatment Translarna.
One important way that pharma companies can deliver true patient advocacy is by bringing cross-functional experience to the table.
Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
The UK government has asked the NHS to start putting together the platforms to allow anonymised primary care patient data to be used by researchers.
Editor's Picks
Newsletters and Deep Dive
digital magazine